keyword
MENU ▼
Read by QxMD icon Read
search

schizophrenia treatment

keyword
https://www.readbyqxmd.com/read/29352548/prediction-of-psychosis-across-protocols-and-risk-cohorts-using-automated-language-analysis
#1
Cheryl M Corcoran, Facundo Carrillo, Diego Fernández-Slezak, Gillinder Bedi, Casimir Klim, Daniel C Javitt, Carrie E Bearden, Guillermo A Cecchi
Language and speech are the primary source of data for psychiatrists to diagnose and treat mental disorders. In psychosis, the very structure of language can be disturbed, including semantic coherence (e.g., derailment and tangentiality) and syntactic complexity (e.g., concreteness). Subtle disturbances in language are evident in schizophrenia even prior to first psychosis onset, during prodromal stages. Using computer-based natural language processing analyses, we previously showed that, among English-speaking clinical (e...
February 2018: World Psychiatry: Official Journal of the World Psychiatric Association (WPA)
https://www.readbyqxmd.com/read/29352540/insight-in-schizophrenia-spectrum-disorders-relationship-with-behavior-mood-and-perceived-quality-of-life-underlying-causes-and-emerging-treatments
#2
Paul H Lysaker, Michelle L Pattison, Bethany L Leonhardt, Scott Phelps, Jenifer L Vohs
Poor insight in schizophrenia is prevalent across cultures and phases of illness. In this review, we examine the recent research on the relationship of insight with behavior, mood and perceived quality of life, on its complex roots, and on the effects of existing and emerging treatments. This research indicates that poor insight predicts poorer treatment adherence and therapeutic alliance, higher symptom severity and more impaired community function, while good insight predicts a higher frequency of depression and demoralization, especially when coupled with stigma and social disadvantage...
February 2018: World Psychiatry: Official Journal of the World Psychiatric Association (WPA)
https://www.readbyqxmd.com/read/29352477/benzodiazepines-for-antipsychotic-induced-tardive-dyskinesia
#3
REVIEW
Hanna Bergman, Paranthaman S Bhoopathi, Karla Soares-Weiser
BACKGROUND: Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazepine group of drugs have been suggested as a useful adjunctive treatment. However, benzodiazepines are very addictive. OBJECTIVES: To determine the effects of benzodiazepines for antipsychotic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder, or other chronic mental illnesses...
January 20, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29352031/can-we-use-mice-to-study-schizophrenia
#4
REVIEW
Sarah Canetta, Christoph Kellendonk
The validity of rodent models for the study of psychiatric disorders is controversial. Despite great efforts from academic institutions and pharmaceutical companies, as of today, no major therapeutic intervention has been developed for the treatment of psychiatric disorders based on mechanistic insights from rodent models. Here, we argue that despite these historical shortcomings, rodent studies are nevertheless instrumental for identifying neuronal circuit mechanisms underlying behaviours that are affected in psychiatric disorders...
March 19, 2018: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
https://www.readbyqxmd.com/read/29347854/a-systematic-review-of-health-economic-models-and-utility-estimation-methods-in-schizophrenia
#5
B Németh, A N Fasseeh, A Molnár, I Bitter, M Horváth, K Kóczián, Á Götze, B Nagy
There is a growing need for economic evaluations describing the disease course, as well as the costs and clinical outcomes related to the treatment of schizophrenia. Areas covered: A systematic review on studies describing health economic models in schizophrenia and a targeted literature review on utility mapping algorithms in schizophrenia were carried out. Models found in the review were collated and assessed in detail according to their type and various other attributes. Fifty-nine studies were included in the review...
January 19, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29346639/comparison-of-dopamine-d3-and-d2-receptor-occupancies-by-a-single-dose-of-blonanserin-in-healthy-subjects-a-positron-emission-tomography-study-with-11c-phno
#6
Amane Tateno, Takeshi Sakayori, Woo-Chan Kim, Kazuyoshi Honjo, Haruo Nakayama, Ryosuke Arakawa, Yoshiro Okubo
Background: Blockade of D3 receptor, a member of the dopamine D2-like receptor family, has been suggested as a possible medication for schizophrenia. Blonanserin has high affinity in vitro for D3 as well as D2 receptors. We investigated whether a single dose of 12 mg blonanserin, which was within the daily clinical dose range (i.e., 8-24 mg) for the treatment of schizophrenia, occupies D3 as well as D2 receptors in healthy subjects. Methods: Six healthy males (mean 35...
January 13, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29345879/improving-long-term-outcomes-in-patients-with-schizophrenia-what-is-the-evidence-for-long-acting-injectable-antipsychotics
#7
Diana O Perkins
Do you consider long-acting injectable (LAI) antipsychotics when selecting among treatments for schizophrenia? Take part in this CME activity to review the evidence for LAIs vs oral medications and to learn which patients may benefit most from this treatment option. Plus, discover the pharmacokinetic properties of LAIs and barriers to their use.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29345690/clozapine-induced-myocarditis
#8
COMMENT
Tanuka Datta, Allen J Solomon
Approved in 1989 for the management of treatment-resistant schizophrenia, Clozapine is a last-line atypical antipsychotic drug used with increasing frequency. In addition to its well-known side effect of agranulocytosis, this drug also carries with it rare but serious adverse cardiovascular risk of myocarditis. We present a patient on Clozapine who was admitted to the cardiology service with chest pain, ST segment elevations and elevated troponin concerning for acute myocardial infarction. Evaluation with imaging revealed decreased left ventricular function, however, no coronary artery disease was present on catheterization; findings consistent with a diagnosis of myocarditis...
January 2018: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/29344345/when-the-drugs-don-t-work-treatment-resistant-schizophrenia-serotonin-and-serendipity
#9
Penelope Lowe, Amir Krivoy, Lilla Porffy, Erna Henriksdottir, Whiskey Eromona, Sukhwinder S Shergill
Treatment-resistant schizophrenia is a serious clinical problem. We adopt a systems-level approach positing a greater role for cognitive control mechanisms in the development of psychotic symptoms and illustrate the clinical application of this via a case report of treatment-resistant patients treated successfully with adjunct pro-cognitive serotonergic medication.
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344344/acetylcholinesterase-inhibitors-in-treatment-resistant-psychotic-depression
#10
Chris Smart, Hamish McAllister-Williams, David Andrew Cousins
Dopamine receptor antagonists can be effective in psychotic depression but response is not assured. Visual hallucinations may arise from a dysregulation of brain cholinergic systems and acetylcholinesterase inhibitors (AChEIs) can treat such hallucinations in dementia with Lewy bodies (DLB). AChEIs have been used in schizophrenia with some success but their efficacy and tolerability in psychotic depression is unclear. This striking case illustrates AChEIs specifically targeting multimodal hallucinations in treatment-resistant depression...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344339/clozapine-discontinuation-in-early-schizophrenia-a-retrospective-case-note-review-of-patients-under-an-early-intervention-service
#11
Andrew Shaker, Rowena Jones
Aim: Research in patients with treatment-resistant schizophrenia has demonstrated that clozapine discontinuation is associated with poor outcomes. There is, however, a paucity of research investigating the impact of clozapine discontinuation specifically in younger patients with more recent onset schizophrenia. A case note review was therefore conducted to ascertain medium-term prognoses in patients with treatment-resistant schizophrenia under an early intervention service (EIS) following clozapine discontinuation...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29343871/-ulysses-contract-in-psychiatry
#12
Andrea Daverio, Gioia Piazzi, Anna Saya
Over the last twenty years we have witnessed a growing focus on the rights of the ill people. The debate on informed consent and a new redefinition of the therapeutic relationship is constantly evolving. With this article, we propose a critical literature review of the so-called "Ulysses contract" or "psychiatric advance directives". It refers to the will that a subject expresses in writing, or orally, about the treatments he or she wishes or does not wish to be subject to if the time comes when it may be impossible to express his/her consent...
November 2017: Rivista di Psichiatria
https://www.readbyqxmd.com/read/29343074/understanding-the-influence-of-antipsychotic-drugs-on-global-methylation-events-and-its-relevance-in-treatment-response
#13
Babu Swathy, Koramannil R Saradalekshmi, Indu V Nair, Chandrasekharan Nair, Moinak Banerjee
AIM: The present study intends to evaluate whether antipsychotic drugs can modulate the host epigenome and if so whether drug-induced epigenetic modulation can explain the heterogeneity in drug response. METHODS: Present study was conducted in in vitro cells and significance of these in vitro observations was further evaluated in a clinical setting, between drug responsive and nonresponsive schizophrenia patients. A number of DNA modifications were assessed at global level using 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine followed by evaluating the expression of epigenetic modifier genes and their crosstalk with miRNAs...
January 18, 2018: Epigenomics
https://www.readbyqxmd.com/read/29342497/non-antipsychotic-catecholaminergic-drugs-for-antipsychotic-induced-tardive-dyskinesia
#14
REVIEW
Hany G El-Sayeh, John Rathbone, Karla Soares-Weiser, Hanna Bergman
BACKGROUND: Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures. OBJECTIVES: 1...
January 18, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29341071/anticholinergic-medication-for-antipsychotic-induced-tardive-dyskinesia
#15
REVIEW
Hanna Bergman, Karla Soares-Weiser
BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia...
January 17, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29341067/vitamin-e-for-antipsychotic-induced-tardive-dyskinesia
#16
REVIEW
Karla Soares-Weiser, Nicola Maayan, Hanna Bergman
BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat people with chronic mental illnesses. Its use, however, is associated with adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Vitamin E has been proposed as a treatment to prevent or decrease TD. OBJECTIVES: The primary objective was to determine the clinical effects of vitamin E in people with schizophrenia or other chronic mental illness who had developed antipsychotic-induced TD...
January 17, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29338621/assessing-the-acute-effects-of-cdp-choline-on-sensory-gating-in-schizophrenia-a-pilot-study
#17
Robert Aidelbaum, Alain Labelle, Ashley Baddeley, Verner Knott
Deficient sensory gating (SG) in schizophrenia is associated with functional outcome and offers a therapeutic target as it is linked to the altered function/expression of the α7 nicotinic acetylcholine receptors (nAChRs). This study analyzed the effects of citicoline (CDP-choline), a supplement with α7 nAChRs agonist properties, on SG in a sample of schizophrenia (SZ) patients. Using a randomized, placebo-controlled, double-blind design the dose-dependent (500 mg, 1000 mg, 2000 mg) and baseline-dependent (deficient versus normal suppressors) effects of CDP-choline on SG were examined using the P50 event-related potential (ERP) index of SG...
January 1, 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29338548/glycine-transporter-1-inhibitors-a-patent-review-2011-2016
#18
Christopher L Cioffi
Numerous research groups have developed GlyT-1 inhibitors in the pursuit of providing a novel antipsychotic treatment for schizophrenia. Despite multiple compounds advancing into clinical trials, a GlyT-1 inhibitor has yet to emerge to treat patients. However, the approach remains heavily investigated as it presents potential therapeutic utility for several other CNS and non-CNS-related indications. Areas covered: This review discusses various GlyT-1 inhibitor chemotypes identified and provides an overview of patent applications filed and published during the period of 2011-2016...
January 17, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29338277/assessment-of-inpatient-psychiatric-readmission-risk-among-patients-discharged-on-an-antipsychotic-polypharmacy-regimen-a-retrospective-cohort-study
#19
Esad Boskailo, Aldin Malkoc, Dustin B McCurry, Jacob Venter, David Drachman, Gilbert M Ramos
OBJECTIVE: Patients are frequently prescribed multiple antipsychotic medications, leading to higher healthcare costs and increased risk for side effects. The efficacy of multiple versus single antipsychotics to prevent acute relapse, measured by incidence of inpatient readmission, is investigated in Arizona, USA. METHOD: A retrospective chart review compared socio-demographic and clinical data from 1,010 patients discharged on a single and 377 discharged on multiple antipsychotic medications...
November 2017: Acta Medica Academica
https://www.readbyqxmd.com/read/29337238/advantages-of-the-alpha-lipoic-acid-association-with-chlorpromazine-in-a-model-of-schizophrenia-induced-by-ketamine-in-rats-behavioral-and-oxidative-stress-evidences
#20
Luis Rafael Leite Sampaio, Francisco Maurício Sales Cysne Filho, Jamily Cunha de Almeida, Danilo Dos Santos Diniz, Cláudio Felipe Vasconcelos Patrocínio, Caren Nádia Soares de Sousa, Manoel Cláudio Azevedo Patrocínio, Danielle S Macêdo, Silvânia Maria Mendes Vasconcelos
Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population. Although its pathophysiological process is not completely elucidated, evidence showing the presence of an oxidative imbalance has been increasingly highlighted in the literature. Thus, the use of antioxidant substances may be of importance for schizophrenia treatment. The objective of this study was to evaluate the behavioral and oxidative alterations by the combination of chlorpromazine (CP) and alpha-lipoic acid (ALA), a potent antioxidant, in the ketamine (KET) model of schizophrenia in rats...
January 11, 2018: Neuroscience
keyword
keyword
55407
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"